The portal-arterial (P-A) insulin gradient and arterial plasma c-peptide levels in the control period (−40 to 0 min) and after administration of the glycogen.

Slides:

Advertisements

Similar presentations

Body weight and oral glucose tolerance in diet-induced obese rats at 5 weeks post-surgery. Body weight and oral glucose tolerance in diet-induced obese.

Advertisements

Improvement of insulin sensitivity by treatment of the annexin A1 receptor agonist in HFD mice. Improvement of insulin sensitivity by treatment of the.

(A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group). (A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group).

a b c d OGTT OGTT *** ** * * Blood glucose (mg/dL) AUC (mg/dL/min) ND

Cyp8b1−/− mice have improved islet insulin secretion and increased islet insulin content but unchanged β-cell mass. Cyp8b1−/− mice have improved islet.

VAN GLP-1R kd disturbed postmeal glycemia and insulinemia but did not impair tolerance of an oral glucose bolus. VAN GLP-1R kd disturbed postmeal glycemia.

BTG2 regulates gluconeogenic gene expression in diabetic mouse models

Effects of insulin administration in streptozotocin-treated mice.

Effect of insulin on hepcidin expression in HepG2 cells.

Comparison of the protective effects of R and S isomers of LA on insulin-stimulated 2-DG uptake. Comparison of the protective effects of R and S isomers.

Body weight, blood glucose, and iron status in STZ-induced type 1 diabetic rats with or without insulin therapy. Body weight, blood glucose, and iron status.

Glucose, insulin, and AGE levels during an OGC before and after RT

Leptin and amylin signaling.

Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.

Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.

GSIS. GSIS. In vivo: serum insulin levels at fasting state and 30 min after glucose injection (A) and the fold change in serum insulin after glucose loading.

Glucose infusion rate required to maintain the hyperglycemic clamp during the experimental period in sedentary and exercised dogs receiving basal or elevated.

α-Cells mainly express SSTR2 and SSTR3

Effect of the acute administration of benzylamine plus vanadate on oral glucose tolerance test in STZ-induced diabetic rats. Effect of the acute administration.

Arterial plasma glucose level and peripheral GIR in conscious dogs during the basal (−40 to 0 min) and experimental (0–240 min) periods treated with vehicle.

Correlation of myotube AdipoR1 (A) and AdipoR2 (B) mRNA expression with insulin secretion (n = 40). Correlation of myotube AdipoR1 (A) and AdipoR2 (B)

A: Insulin-stimulated total, oxidative, and nonoxidative glucose disposal in subjects with NGT (open bars), IFG (dotted bars), IGT (striped bar), IFG/IGT.

Modulation of insulin sensitivity by IL-6 in mice: A lack of PTP1B prevents chronic effects of IL-6. Modulation of insulin sensitivity by IL-6 in mice:

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

Mean ± SEM concentration of insulin in plasma and CSF and glucose in plasma 30 min after the intraperitoneal administration of DET or NPH insulin at different.

Appearance of insulin in plasma and CSF at different times after the administration of subcutaneous DET and GLAR in mice and the effect of chronic DET.

Measurement of insulin release from islets evoked by glucose, diazoxide, and high K+. Measurement of insulin release from islets evoked by glucose, diazoxide,

Glucose tolerance in WT and TRPM2-KO mice.

Unlabeled and tracer glucocorticoids in plasma from arterialized samples and veins draining skeletal muscle and subcutaneous adipose tissue. Unlabeled.

Transgenic restoration of long-chain n-3 PUFA protects against obesity-linked insulin resistance and glucose intolerance. Transgenic restoration of long-chain.

Glycogen synthase and glycogen phosphorylase activities after in vivo AICAR treatment. Glycogen synthase and glycogen phosphorylase activities after in.

A: Total number of neurons in L5 dorsal root ganglia of long-term diabetic, recovered, and nondiabetic mice. A: Total number of neurons in L5 dorsal root.

Inhibition of glucagon-induced glycogenolysis in human primary hepatocytes. Inhibition of glucagon-induced glycogenolysis in human primary hepatocytes.

Fig. 2 HHKO mice exhibit improved glucose tolerance by increasing plasma incretin levels and insulin secretion. HHKO mice exhibit improved glucose tolerance.

ATL-801 treatment increases insulin sensitivity in KKAY mice.

Fig. 4 Deletion of hepatocyte HIF-2α does not affect obesity-induced glucose, glucagon, and insulin intolerance. Deletion of hepatocyte HIF-2α does not.

Arterial and portal plasma glucagon levels and the portal-arterial (P-A) glucagon gradient in the control period (−40 to 0 min) and after administration.

Total plasma BCAA (A) and C3 and C5 acylcarnitine (AC) (B) concentrations in the basal state and during insulin infusion in obese subjects before and after.

CPPED1 (A) and PPARγ2 (B) mRNA expressions in cultured SGBS cells during adipocyte differentiation. CPPED1 (A) and PPARγ2 (B) mRNA expressions in cultured.

Phosphorylated CREB levels were assessed in the hippocampus at 20 min after cue and contextual fear conditioning. Phosphorylated CREB levels were assessed.

Sympathetic denervation decreases VLDL-TG secretion in the fasted state. Sympathetic denervation decreases VLDL-TG secretion in the fasted state. A: Plasma.

Effect of anandamide on blood glucose clearance and insulin sensitivity. Effect of anandamide on blood glucose clearance and insulin sensitivity. A: Intraperitoneal.

Plasma concentrations of glucose, insulin, C-peptide and glucagon observed in subjects with NFG/NGT, NFG/IGT, IFG/NGT, and IFG/IGT-D following ingestion.

Mean (±SE) plasma glucose concentrations before, during, and after infusions of octreotide (with growth hormone) with saline (•), with insulin replacement.

Npas4 is a stress-induced factor in pancreatic β-cells.

Mice fed GP-SPI diet show improved fasting glucose and oral glucose tolerance. Mice fed GP-SPI diet show improved fasting glucose and oral glucose tolerance.

Food intake in response to central infusion of glucose (squares) or insulin (triangles) and in response to successive central infusion of insulin, insulin.

Treatment of high-fat diet–fed mice with TTR-ASOs decreases circulating TTR and RBP4 levels, and improves insulin sensitivity. Treatment of high-fat diet–fed.

Treatment of ob/ob mice with TTR-ASOs improves insulin sensitivity.

Effects of berberine on in vivo metabolism in two animal models of insulin resistance. Effects of berberine on in vivo metabolism in two animal models.

Leucine deprivation increases energy expenditure.

Average percent change in serum leptin and soluble leptin receptor (sOB-R) levels in response to rhLeptin administration at a low dose (0.01 mg/kg) (n.

Arterial and hepatic sinusoidal plasma insulin levels in conscious dogs during the basal (−40 to 0 min) and experimental (0–240 min) periods treated with.

Loss of Phb2 in β-cells induces development of diabetes over a 3-week period in β-Phb2−/− mice. Loss of Phb2 in β-cells induces development of diabetes.

Pioglitazone administration acutely inhibits insulin secretion and increases insulin clearance in Wistar rats. Pioglitazone administration acutely inhibits.

Chronic rapamycin treatment impairs β-cell mass and insulin clearance in rats. Chronic rapamycin treatment impairs β-cell mass and insulin clearance in.

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Effects of GIP and GLP-1 infusion on MR-proANP levels.

Glycemic control and body weight over 52 weeks.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Postprandial glucose, insulin and glucagon-like peptide-1 (GLP-1) levels following carbohydrate-first (CF), carbohydrate-last (CL) and sandwich (S) meal.

Effects of d-xylose or sucralose (control) with or without sitagliptin on gastric emptying (half-emptying time [T50]) (n = 12). Effects of d-xylose or.

Subodh Verma et al. BTS 2018;3:

Changes in the plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) level from baseline to treatment titration and 3 months of therapy: full analysis.

(A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects. (A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects.

Comparison of sympathetic activity, endothelial function and baroreflex sensitivity between differing metabolic risk categories (n=54). Comparison of sympathetic.

A: Diet-specific postprandial responses to glucose and NEFA levels.

Four–time point diurnal profiles of plasma glucose concentrations (A) and AUCs (B) over quintiles of HbA1c. ○, AUC1; •, AUC2; ▴, AUC2 − AUC1 (differences.

Pharmacodynamic and pharmacokinetic evaluation of EXE-RM-LNC in a high-fat diet (HFD)-induced obese/diabetic mouse model following acute treatment. Pharmacodynamic.

Presentation transcript:

The portal-arterial (P-A) insulin gradient and arterial plasma c-peptide levels in the control period (−40 to 0 min) and after administration of the glycogen phosphorylase inhibitor (0 to 180 min) in CON and PDN 18-h fasted conscious dogs. The portal-arterial (P-A) insulin gradient and arterial plasma c-peptide levels in the control period (−40 to 0 min) and after administration of the glycogen phosphorylase inhibitor (0 to 180 min) in CON and PDN 18-h fasted conscious dogs. Data are expressed as mean ± SE. Statistical comparisons were made by two-way ANOVA with repeated-measures design, and post hoc analysis was performed with use of the univariate F test when appropriate. *P < 0.05 versus basal period; n = 7 for CON and PDN. Stephanie M. Sherck et al. Diabetes 2001;50:2487-2496 ©2001 by American Diabetes Association